CAR T-cell Therapy Market Expected to Witness a Sustainable Growth Over 2026 | Celgene, Novartis, Gilead, Pfizer, CARsgen Therapeutics

Global CAR T-cell Therapy Market research report offers concise and complete information about emerging market segments in CAR T-cell Therapy industry and market driving factors which will boost the decision-making process. Moreover, market statistics information from 2020 to 2026, top market players in CAR T-cell Therapy market, their company profile, market share, segmentation, and geographical overview of the industry will help the readers in planning their business strategies.

Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor. Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors. CAR-T cells can be either derived from T cells in a patient's own blood (autologous) or derived from the T cells of another healthy donor (allogenic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.

Get Sample Copy of this Report (Includes Business Impact of COVID-19)
https://www.marketinsightsreports.com/reports/01291802837/global-car-t-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?source=openpr&Mode=07

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global CAR T-cell Therapy Market: Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics, Mustang Bio, Bluebird Bio, Collectis, Allogene Therapeutics, Celyad and others.

Latest Industry News:

May 05, 2020, BOSTON & SOUTH SAN FRANCISCO, Calif.- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Portola's commercialized medicine, Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. The acquisition will add near-term diversification to Alexion's commercial portfolio and provides the opportunity to apply the company's demonstrated global commercial excellence to create long-term value for patients and shareholders. The merger agreement has been unanimously approved by the boards of Alexion and Portola.

MAY 06, 2020 - KENILWORTH, N.J - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from RESTORE-IMI 2, a randomized, controlled, double-blind Phase 3 clinical trial evaluating RECARBRIO(TM) (imipenem, cilastatin, and relebactam) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). The results demonstrated noninferiority of RECARBRIO compared to piperacillin and tazobactam (PIP/TAZ), the active comparator, in the primary and key secondary endpoints of the study, 28-day all-cause mortality and clinical response, respectively. In February 2020, the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for use of RECARBRIO in this patient population. The FDA Prescription Drug User Fee Act (PDUFA) goal date is June 4, 2020. Phase 3 trial data are now available in a compendium of presentations posted by Merck, coinciding with publication of study abstracts by the 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

May 6, 2020 - The FDA has approved a new use for AstraZeneca's Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fraction heart failure, with or without type 2 diabetes.

Global CAR T-cell Therapy Market Split by Product Type and Applications:
This report segments the global CAR T-cell Therapy market on the basis of Types are:
Allogeneic
Autologous

On the basis of Application, the Global CAR T-cell Therapy market is segmented into:
Hospitals
Cancer Research Centers
Others

Regional Analysis For CAR T-cell Therapy Market:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Browse the report description and TOC:
https://www.marketinsightsreports.com/reports/01291802837/global-car-t-cell-therapy-market-size-status-and-forecast-2020-2026?source=openpr&Mode=07

Influence of the CAR T-cell Therapy Market Report:

-Comprehensive assessment of all opportunities and risk in the CAR T-cell Therapy market.
-Detailed study of business strategies for growth of the CAR T-cell Therapy market-leading players.
-Conclusive study about the growth plot of CAR T-cell Therapy market for forthcoming years.
-In-depth understanding of CAR T-cell Therapy market-particular drivers, constraints and major micro markets.
-Favourable impression inside vital technological and market latest trends striking the CAR T-cell Therapy market.

What are the market factors that are explained in the report?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global CAR T-cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter's five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Purchase Full report:
https://www.marketinsightsreports.com/report/purchase/01291802837?mode=su?source=openpr&Mode=07

We Offer Customization On Report Based On Specific Client Requirement:
- Free country Level analysis for any 5 countries of your choice.
- Free Competitive analysis of any 5 key market players.
- Free 40 analyst hours to cover any other data point.

Browse More Reports:

Global CAR T-Cell Therapy For Multiple Myeloma Market
https://www.marketinsightsreports.com/reports/05301265259/global-car-t-cell-therapy-for-multiple-myeloma-market-size-status-and-forecast-2019-2025?Mode=07

Global Allogeneic Stem Cell Therapy Market
https://www.marketinsightsreports.com/reports/04201996600/global-allogeneic-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=07

Global Autologous Cell Therapy Market
https://www.marketinsightsreports.com/reports/07241367279/global-autologous-cell-therapy-market-2019-by-company-regions-type-and-application-forecast-to-2024?Mode=07

Contact Us:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.